Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.

Oncotarget - 2 Feb 2016

Yang Shuqun, Luo Chonglin, Gu Qingyang, Xu Qiang, Wang Guan, Sun Hongye, Qian Ziliang, Tan Yexiong, Qin Yuxin, Shen Yuhong, Xu Xiaowei, Chen Shu-Hui, Chan Chi-Chung, Wang Hongyang, Mao Mao, Fang Douglas D

Abstract excerpt

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an excellent in vivo system for understanding of disease biology and drug discovery. In order to identify new therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Janus Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to STAT3 Transcription Factor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26701727
DOI: 10.18632/oncotarget.6684
PMCID: PMC4868698

Genes

JAK1
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.PMID 26701727Read ↗

Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinomaSemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

JAK Inhibition in STAT1 Gain-of-Function–Mediated Treatment-Resistant Autoimmune HepatitisSemantic proximity Read ↗

JAK-STAT pathway in hematological malignancies: achievements, challenges and future perspectivesSemantic proximity Read ↗

Emerging Signaling Pathways in Hepatocellular CarcinomaSemantic proximity Read ↗

The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumorsSemantic proximity Read ↗

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.Semantic proximity Read ↗

HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenibSemantic proximity Read ↗

An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling componentsSemantic proximity Read ↗

The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma.Semantic proximity Read ↗

Integrating bulk and single-cell RNA sequencing reveals<i>SH3D21</i>promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathwaySemantic proximity Read ↗

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.